Skip to main content
. Author manuscript; available in PMC: 2022 Oct 13.
Published in final edited form as: Sci Transl Med. 2021 Sep 8;13(610):eabf0376. doi: 10.1126/scitranslmed.abf0376

Fig. 8. Short-term in vivo treatment with anti-LTBP4 human antibody in combination with prednisone enhanced muscle performance and protected against injury in dystrophic mice.

Fig. 8.

(A) mdxD2 male mice were injected intraperitoneally with either dimethyl sulfoxide (DMSO) vehicle, anti-LTBP4 at 20 mg/kg, prednisone at 1 mg/kg, or antibody (20 mg/kg) and prednisone (1 mg/kg). Injections were weekly for 4 weeks starting at 8 weeks of age and completing at 12 weeks of age. Arrowheads indicate injection timing. (B) Treatment with anti-LTBP4 antibody co-administered with prednisone attenuated force loss in treated TA muscles to be similar to WT controls. (C) Body mass was not altered after 4 weeks of treatment. *P < 0.05 by one-way ANOVA. n = 5 mice per mdxD2 group. n = 3 WT controls.